Statement on Potential Intersection between PFAS Exposure and COVID-19:
CDC/ATSDR understands that many of the communities we are engaged with are concerned about how PFAS exposure may affect their risk of COVID-19 infection. We agree that this is an important question.
CDC/ATSDR recognizes that exposure to high levels of PFAS may impact the immune system. There is evidence from human and animal studies that PFAS exposure may reduce antibody responses to vaccines (Grandjean et al., 2017, Looker et al., 2014), and may reduce infectious disease resistance (NTP, 2016). Because COVID-19 is a new public health concern, there is still much we don’t know. More research is needed to understand how PFAS exposure may affect illness from COVID-19.
A large number of studies have examined possible relationships between levels of per- and polyfluoroalkyl substances (PFAS) in blood and harmful health effects in people. However, not all of these studies involved the same groups of people, the same type of exposure, or the same PFAS. These different studies therefore reported a variety of health outcomes. Research involving humans suggests that high levels of certain PFAS may lead to the following:
Increased cholesterol levels
Decreased vaccine response in children
Changes in liver enzymes
Increased risk of high blood pressure or pre-eclampsia in pregnant women
Small decreases in infant birth weights
Increased risk of kidney or testicular cancer
At this time, scientists are still learning about the health effects of exposures to mixtures of different PFAS.
One way to learn about whether PFAS will harm people is to do studies on lab animals.
Humans and animals react differently to PFAS, and not all effects observed in animals may occur in humans. Scientists have ways to estimate how the exposure and effects in animals compare to what they would be in humans.
Additional research may change our understanding of the relationship between exposure to PFAS and human health effects.